This Article Full Text Full Text (PDF) Services E-mail this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meissner, H. C. Search for Related Content PubMed Articles by Meissner, H. C. Related Collections Related Article

PEDIATRICS Vol. 112 No. 6 December 2003, pp. 1447-1452

TECHNICAL REPORT

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

ABSTRACT

Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe respiratory syncytial virus (RSV) infections in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This report summarizes the clinical trial information on which the guidance in the accompanying policy statement for administering RSV prophylaxis to certain children with a history of preterm birth, chronic lung disease, or congenital heart disease is based. On the basis of results of a recently completed clinical trial, palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks’ gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present.

Abbreviations: RSV, respiratory syncytial virus • RSV-IGIV, Respiratory Syncytial Virus Immune Globulin Intravenous • CLD, chronic lung disease • CHD, congenital heart disease • BPD, bronchopulmonary dysplasia • ICU, intensive care unit

This article has been cited by other articles:

				J. Rogers, R.J. Schoepp, O. Schroder, T.L. Clements, T.F. Holland, J.Q. Li, J. Li, L.M. Lewis, R.P. Dirmeier, G.J. Frey, et al. Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases Protein Eng. Des. Sel., May 13, 2008; (2008) gzn027v1. [Abstract] [Full Text] [PDF]

				J. Gooding, A. Millage, A.-K. Rye, and R. Lacroix The Cost and Safety of Multidose Use of Palivizumab Vials Clinical Pediatrics, March 1, 2008; 47(2): 160 - 163. [Abstract] [PDF]

				Section on Surgery and the Committee on Fetus and Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia Pediatrics, March 1, 2008; 121(3): 627 - 632. [Abstract] [Full Text] [PDF]

				E. Khemani, D. B. McElhinney, L. Rhein, O. Andrade, R. V. Lacro, K. C. Thomas, and M. P. Mullen Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era Pediatrics, December 1, 2007; 120(6): 1260 - 1269. [Abstract] [Full Text] [PDF]

				E. A.F. Simoes Maternal Smoking, Asthma, and Bronchiolitis: Clear-Cut Association or Equivocal Evidence? Pediatrics, June 1, 2007; 119(6): 1210 - 1212. [Full Text] [PDF]

				Brief Report: Respiratory Syncytial Virus Activity--United States, 2005-2006 JAMA, January 24, 2007; 297(4): 356 - 357. [Full Text] [PDF]

				Brief Report: Respiratory Syncytial Virus Activity--United States, 2004-2005 JAMA, January 18, 2006; 295(3): 267 - 268. [Full Text] [PDF]

				P. Manzoni, U. Sala, G. Gomirato, A. Coscia, and C. Fabris Optimal Timing and Dosing Intervals of Palivizumab in Premature Neonates: Still Some Work to Do Pediatrics, May 1, 2005; 115(5): 1439 - 1440. [Full Text] [PDF]

				R. T. Nicolas, C. Hills, J. H. Moller, C. B. Huddleston, and M. C. Johnson Early Outcome After Glenn Shunt and Fontan Palliation and the Impact of Operation During Viral Respiratory Season: Analysis of a 19-year Multi-Institutional Experience Ann. Thorac. Surg., February 1, 2005; 79(2): 613 - 617. [Abstract] [Full Text] [PDF]

				L. E. Yount and W. T. Mahle Economic Analysis of Palivizumab in Infants With Congenital Heart Disease Pediatrics, December 1, 2004; 114(6): 1606 - 1611. [Abstract] [Full Text] [PDF]

				R. C. Holman, A. T. Curns, J. E. Cheek, J. S. Bresee, R. J. Singleton, K. Carver, and L. J. Anderson Respiratory Syncytial Virus Hospitalizations Among American Indian and Alaska Native Infants and the General United States Infant Population Pediatrics, October 1, 2004; 114(4): e437 - e444. [Abstract] [Full Text] [PDF]

				A Duppenthaler, R A Ammann, M Gorgievski-Hrisoho, J-P Pfammatter, and C Aebi Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease Arch. Dis. Child., October 1, 2004; 89(10): 961 - 965. [Abstract] [Full Text] [PDF]

				C. B. Hall Managing Bronchiolitis and Respiratory Syncytial Virus: Finding the Yellow Brick Road Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 111 - 112. [Full Text] [PDF]

				Committee on Infectious Diseases and Committee on Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections Pediatrics, December 1, 2003; 112(6): 1442 - 1446. [Abstract] [Full Text] [PDF]